阿波托克斯获得权利,在加拿大为男性低效症分配Nebido睾丸激素疗法。 Apotex acquires rights to distribute testosterone therapy Nebido in Canada for male hypogonadism.

Grünenthal已许可专有权在加拿大向加拿大最大的制药公司Apotex分发长效睾丸酮疗法Nebido。 Grünenthal has licensed exclusive rights to distribute Nebido®, a long-acting testosterone therapy, in Canada to Apotex, Canada’s largest pharmaceutical company. Apotex旗下的Searchlight Pharma将寻求监管批准，并将该药用于治疗男性性腺功能减退症，这是一种影响许多50岁以上男性且常未被治疗的疾病。 Apotex’s Searchlight Pharma will seek regulatory approval and market the drug for male hypogonadism, a condition affecting many men over 50 that often goes untreated. 这笔交易包括Grünenthal的预付和里程碑付款,外加销售份额。 The deal includes upfront and milestone payments for Grünenthal, plus a share of sales. 它扩大了Apotex的专业护理组合,加强了Grünenthal的全球影响力,在现有的合作基础上更进一步。 It expands Apotex’s specialty care portfolio and strengthens Grünenthal’s global reach, building on an existing collaboration.